Publications

Add filters (0)

46 results

Fundamentals of osteoarthritis: Biomarkers.

October 10, 2026

Osteoarthritis Cartilage

Abstract OBJECTIVE To provide a practical framework for understanding biomarker principles and applications in osteoarthritis (OA). METHODS We summarize current biomarker science and highlight advances since the 2022 Fundamentals in OA biomarkers review. RESULTS OA biomarker research has evolved from single-analyte studies to large-scale proteomics, multi-omics, and predictive modeling, while established extracellular matrix biomarkers remain […]

Read publication

Can obesity pharmacotherapy modify osteoarthritis? Interpreting pain relief, weight-loss quality, and structural outcomes.

September 21, 2026

Osteoarthritis Cartilage

Abstract OBJECTIVE To evaluate the emerging role of obesity pharmacotherapies, particularly glucagon-like peptide-1 (GLP-1) receptor agonists and multi-agonists, in osteoarthritis (OA) management, by examining the interpretation of pain outcomes, potential structural joint effects, the importance of weight-loss quality, implications for time to total joint replacement (TJR), and the patient populations most likely to benefit from […]

Read publication

The role of type I collagen fragment C1M in knee osteoarthritis. A longitudinal biomarker study using data from the OA-FNIH consortium.

June 1, 2026

Osteoarthritis Cartilage

Abstract OBJECTIVE To evaluate the association of neoepitopes from type I and II collagen with knee osteoarthritis (OA) progression phenotypes using data from the OA-FNIH biomarker consortium, with comparison to associations of the other biomarkers assessed in this sample during the consortium’s phase 1 analysis. DESIGN Serum (s) and urinary (u) neoepitopes of type I […]

Read publication

Longitudinal stability of molecular endotypes of knee osteoarthritis patients.

January 1, 2025

Osteoarthritis Cartilage

Abstract OBJECTIVE To assess the longitudinal stability of biomarker-based molecular endotypes of knee osteoarthritis (KOA) participants from APPROACH and to evaluate the consistency of findings in an independent KOA population. METHODS Nineteen biomarkers were measured longitudinally in 295 KOA participants from the APPROACH cohort. K-means clustering was used to identify the structural damage, inflammation, and […]

Read publication

Reflections from the OARSI 2022 clinical trials symposium: The pain of OA-Deconstruction of pain and patient-reported outcome measures for the benefit of patients and clinical trial design.

October 1, 2023

Osteoarthritis Cartilage

Abstract OBJECTIVE Osteoarthritis (OA) drug development is hampered by a number of challenges. One of the main challenges is the apparent discordance between pain and structure, which has had a significant impact on drug development programs and has led to hesitance among stakeholders. Since 2017, the Clinical Trials Symposium (CTS) has been hosted under the […]

Read publication

Clinical monitoring in osteoarthritis: Biomarkers.

September 1, 2022

Osteoarthritis Cartilage

Abstract OBJECTIVE The purpose of this overview of osteoarthritis (OA) biomarkers is to provide the non-specialist with a toolbox, based on experience acquired by biomarker researchers over many years, to understand biomarkers in general and their use in the OA field. METHODS We provide an update on this subject since the OARSI Primer on osteoarthritis […]

Read publication

The association of the lipid profile with knee and hand osteoarthritis severity: the IMI-APPROACH cohort.

August 1, 2022

Osteoarthritis Cartilage

Abstract OBJECTIVE To investigate the association of the lipidomic profile with osteoarthritis (OA) severity, considering the outcomes radiographic knee and hand OA, pain and function. DESIGN We used baseline data from the Applied Public-Private Research enabling OsteoArthritis Clinical Headway (APPROACH) cohort, comprising persons with knee OA fulfilling the clinical American College of Rheumatology classification criteria. […]

Read publication

Low levels of type II collagen formation (PRO-C2) are associated with response to sprifermin: a pre-defined, exploratory biomarker analysis from the FORWARD study.

January 1, 2022

Osteoarthritis Cartilage

Abstract OBJECTIVE Osteoarthritis (OA) is characterized by the gradual loss of cartilage. Sprifermin, a recombinant FGF18, is being developed as a cartilage anabolic drug. PRO-C2 is a serum marker of type II collagen formation and low levels have been shown to be prognostic of radiographic progression. The aim of the study was to investigate whether […]

Read publication

Does moderate intensity impact exercise and non-impact exercise induce acute changes in collagen biochemical markers related to osteoarthritis? – An exploratory randomized cross-over trial.

July 1, 2021

Osteoarthritis Cartilage

Abstract OBJECTIVE To investigate acute changes in biochemical markers of cartilage turnover in response to moderate intensity exercise with and without joint impact in humans with knee osteoarthritis. DESIGN We conducted a randomized, cross-over, exploratory clinical study. Twenty subjects with knee osteoarthritis (OA) were randomized, of which twenty completed 30 min of cycling and 15 completed […]

Read publication